Reduce head count by cutting Reps who only sell Crestor

Quote

Anonymous

Guest
The contract sales force should be the only team selling Crestor alone. Why are we paying over 100k a year for sales people who only sell one product!! Really senseless and a total of waste of money.
These reps have had a free ride for way to long. Time to send them to unemployment. Sad truth and even they know it.
 




Anonymous said:
The contract sales force should be the only team selling Crestor alone. Why are we paying over 100k a year for sales people who only sell one product!! Really senseless and a total of waste of money.
These reps have had a free ride for way to long. Time to send them to unemployment. Sad truth and even they know it.
Click to expand...

Too bad it's all done with force ranking.
 








Really! Our biggest money maker. Let's get rid of the experienced reps who have established access and relationships in their territories. That will really save the company won't it? Short term thinking for a long term problem. Just stay in your role as a CSA. Jerk!
 




Crestor was the biggest moneymaker at AZ. That will begin to end soon, even though patent coverage runs till 2016. Sales will begin to drop by double digits when generic exclusivity expires this summer on generic Lipitor and the price for it drops to commodity levels. Crestor may be marginally better than Lipitor in some regards, but as far as actual health outcomes, there is no proof of any difference at all between the two. Patients won't want to pay 50x as much for that. Some sales will continue, but they will be dwindling over time now most likely, even well before the patent expiry, as new scripts will go t the generics
 




disagree...Crestor still has alot of growth left. Samples make a big difference, in terms of cost savings for the patient, assessing tolerability, and just sending the patient home with something.

Additionally, Crestor is differentiated in a number of ways. Pathway and low dose probably being the most pertinent. The implied benefit is, why use a high dose statin in a crowded pathway -- 3a4 -- when you can use a low dose Crestor that occupies a completely DIFFERENT pathway. Simvastatin revisions embolden that perspective, and who knows what we'll see with generic lipitor...increased incidence in myalgias??? That's the great unknown.

Crestor is really a great drug. Why do you think so many Doctors themselves are on it???
 




Anonymous said:
The contract sales force should be the only team selling Crestor alone. Why are we paying over 100k a year for sales people who only sell one product!! Really senseless and a total of waste of money.
These reps have had a free ride for way to long. Time to send them to unemployment. Sad truth and even they know it.
Click to expand...


Yeah that makes sense.... take the drug that brings in the money, and dump the reps.

Atorvastatin will kill it you say? Maybe, but even at 50% loss it makes more money in sales than Symbicort does.
 




Anonymous said:
disagree...Crestor still has alot of growth left. Samples make a big difference, in terms of cost savings for the patient, assessing tolerability, and just sending the patient home with something.

Additionally, Crestor is differentiated in a number of ways. Pathway and low dose probably being the most pertinent. The implied benefit is, why use a high dose statin in a crowded pathway -- 3a4 -- when you can use a low dose Crestor that occupies a completely DIFFERENT pathway. Simvastatin revisions embolden that perspective, and who knows what we'll see with generic lipitor...increased incidence in myalgias??? That's the great unknown.

Crestor is really a great drug. Why do you think so many Doctors themselves are on it???
Click to expand...

Great points all for certain classes of patients, but cost will drive the insurers to make most new patients try the generic first, especially as the price difference becomes more massive. Crestor will eventually only get the cases where the generic had some of the issues you mention above become relevant.
 








Anonymous said:
Yeah that makes sense.... take the drug that brings in the money, and dump the reps.

Atorvastatin will kill it you say? Maybe, but even at 50% loss it makes more money in sales than Symbicort does.
Click to expand...

Th respiratory products are unfairly protected. Fante has as oft spot for them having fu cke d up many launches. He puts his belief in that portfolio ahead of common sense.

He buried Zomig to increase the resource on RAQ. And of course he was key to the debacle with pth.

Symbicort is like family to him. He's really not very good at what he does. Ever. But I suspect he'll parlay it into a huge payout, and then bs his way into some other place he can close the doors in.
 




Anonymous said:
Yeah that makes sense.... take the drug that brings in the money, and dump the reps.

Atorvastatin will kill it you say? Maybe, but even at 50% loss it makes more money in sales than Symbicort does.
Click to expand...

Th respiratory products are unfairly protected. Fante has as oft spot for them having fooked up many launches. He puts his belief in that portfolio ahead of common sense.

He buried Zomig to increase the resource on RAQ. And of course he was key to the debacle with pth.

Symbicort is like family to him. He's really not very good at what he does. Ever. But I suspect he'll parlay it into a huge payout, and then bs his way into some other place he can close the doors in.
 




Symbicort is protected due to the belief that the delivery device market entry barrier will protect its patent expiring competitor from rapid generic market entry. We'll see. These devices aren't really that complicated, but it does still require an expensive tedious FDA drug delivery validation study.

By the way, both AZ and GSK are spending really big bucks on Direct to consumer TV advertising right now for their respective branded products.
 












I'm actually interviewing for a position that will solely promote Crestor. However, as I understand it, there are a few in the pipeline that will be added to the portfolio soon.... Is it a bad choice to come on now???
 




Top Bottom
Back
Quote